|
Á¦¸ñ : [³×¿ÀÀ̹ÃÅØ] ¢º³×¿À ½ÃÃÑ ±Ô¸ðÀÇ ÀûÀý¼ºÀ» º¸½Ã·Á¸é ¸ÞµåÆÑÅä¿Í ºñ±³Çϼ¼¿ä. ¢¸ |
|
±Û¾´ÀÌ : IPO¸Å´Ï¾Æ |
ÀÛ¼ºÀÏ : 2021-03-06 12:30:12 |
Á¶È¸¼ö : 4567 Ãßõ¼ö : 29 |
|
|
Loading Time [ Sec ] CI950220 |
³×¿ÀÀ̹ÃÅØ ½Ã°¡ÃÑ¾× ±Ô¸ðÀÇ ÀûÀý¼º¿¡ ´ëÇؼ Æò°¡¸¦ ÇÏ°í ½ÍÀ¸½Ã¸é
°°Àº ¸é¿ªÇ×¾ÏÁ¦ ºÐ¾ßÀÇ ÀÓ»óÀ» ÇÏ°í ÀÖ´Â ¸ÞµåÆÑÅä¿Í ºñ±³ÇØ º¸½Ã¸é µË´Ï´Ù. ³×¿ÀÀ̹ÃÅØÀÇ T¼¼Æ÷ ÁõÆøÀ» ½ÃÅ°´Â ÇÏÀÌ·çŲÀÌ ¸ÞµåÆÑÅäÀÇ TGF-º£Å¸ ¼ö¿ëü º¸´Ù ÇѼö~µÎ¼ö À§ ´Ü°èÀÔ´Ï´Ù. È®À强 ¹× È¿´É¿¡¼ ¼Ó¼Ó ÀÔÁõÀÌ µÇ°í ÀÖ½À´Ï´Ù. »ïÁßÀ½¼º À¯¹æ¾Ï¿¡¼ Å°Æ®·ç´Ù ´Üµ¶¿¡¼´Â 5% ¹ÝÀÀÀ²À» º¸¿´´Âµ¥ ÇÏÀÌ·çŲ°ú º´¿ë¿¡¼´Â °ÅÀÇ 30% °¡±î¿î ¹ÝÀÀÀ²À» º¸¿´½À´Ï´Ù. ±×¸®°í Äڷγª Ä¡·áÁ¦ ÀÓ»óÀ» 12¿ùºÎÅÍ ¹Ì±¹¿¡¼ Åõ¿©ÇÏ¿©, Á¶¸¸°£ Áß°£ ¹ßÇ¥ ÇÒ ¿¹Á¤ÀÔ´Ï´Ù. Äڷγª Ä¡·áÁ¦¿¡¼ ÇÙ½ÉÀûÀÎ µÎ°¡Áö°¡ ÁßÈÇ×ü¿Í T¼¼Æ÷ ÁõÆøÀÔ´Ï´Ù. ±×Áß¿¡¼ T¼¼Æ÷ ÁõÆøÀÌ ´õ Áß¿äÇÏ´Ù´Â °ÍÀÌ ÃÖ±Ù ÀÔÁõµÇ°í ÀÖ½À´Ï´Ù. ³ªÀÌ°¡ µé¸é ¸é¿ª¼¼Æ÷ÀÎ T¼¼Æ÷·®ÀÌ ÁÙ¾îµå´Âµ¥, ±×·¡¼ ³ëÀκеéÀÌ Äڷγª¿¡ ´õ Ãë¾àÇÑ °ÍÀÔ´Ï´Ù. ³×¿ÀÀ̹ÃÅØÀÇ ÇÏÀÌ·çŲÀÌ T¼¼Æ÷ ÁõÆøÀ» ½ÃÅ´À¸·Î½á Äڷγª¸¦ ºü¸£°Ô Ä¡·áÇÒ ¼ö ÀÖ´Â ±â´ÉÀ» ÇØ ÁÖ´Â °ÍÀÔ´Ï´Ù. ¸é¿ªÇ×¾ÏÁ¦ÀÇ 3´ë ´ëÀåÀÎ ¸ÓÅ©, ·Î½´, BMS¶û º´¿ëµµ ÇÔ²² ÇÏ°í ÀÖ½À´Ï´Ù. ÇöÀç ¸ÞµåÆÑÅä°¡ ½Ã°¡ÃÑ¾× 1.7Á¶ Á¤µµ µË´Ï´Ù. ³×¿ÀÀ̹ÃÅØÀº ÇöÀç 7000¾ï Á¶±Ý ³Ñ½À´Ï´Ù. ¸ÞµåÆÑÅä¶û ºñ±³ÇÏ¸é ³×¿À´Â ÃÖ¼Ò 2Á¶´Â ³Ñ¾î°¡¾ß Á¤»óÀÔ´Ï´Ù. ù³¯ µû»óÀº ÀÏ´Ü ±âº»ÀÔ´Ï´Ù. 1300´ë 1À» ³Ñ´Â ±â°ü ¼ö¿äÁ¶»ç¿¡ û¾à¿¡¼ Çϳª±ÝÀ¶Àº 1100´ë 1ÀÌ ³Ñ¾úÀ¸¸ç, ¹Ì·¡¿¡¼Â¿¡¼´Â 850´ë 1À» ³Ñ¾ú½À´Ï´Ù. Àß ºñ±³Çϼż ÅõÀÚÇϽñ⠹ٶø´Ï´Ù.
°ø°¨ÇϽøé Ãßõ ´·¯ÁÖ½Ã¸é °í¸¿°Ú½À´Ï´Ù.
³×¿ÀÀ̹ÃÅØ ÆÄÀÌÇÁ¶óÀÎÀÔ´Ï´Ù.
Disease Area | Study | Indication / Combination | ¡¡ | ¡¡ | ¡¡ | ¡¡ | ONCOLOGY | NIT-106 | High Risk Skin Cancers / TECENTRIQ | ÀÓ»ó 2»ó (·Î½´) | ¡¡ | NIT-110 | Solid Tumors1 / KEYTRUDA (KEYNOTE-A60) | ÀÓ»ó 2»ó (¸ÓÅ©) | ¡¡ | GX-I7-CA-006 | TNBC / KEYTRUDA (KEYNOTE-899) 2 | ÀÓ»ó 2»ó (¸ÓÅ©) | ¡¡ | NIT-109 | Gastric, GEJ, & EAC / OPDIVO | ÀÓ»ó 2»ó (BMS) | NIT-119 | NSCLC (1L) / TECENTRIQ | ÀÓ»ó 2»ó (¸ÓÅ©) | NIT-112 | LBCL / KYMRIAH | ÀÓ»ó 1»ó | ¡¡ | ¡¡ | NIT-104 | GBM (single dose) | ÀÓ»ó 1»ó | ¡¡ | ¡¡ | NIT-107 | GBM (multi dose)3 | ÀÓ»ó 2»ó (¿ö½ÌÅÏ´ëÇб³) | ¡¡ | NIT-115 | SCCHN3,4 | ÀÓ»ó 1»ó (UCSF) | ¡¡ | ¡¡ | IMMUNOLOGY | NIT-116 | COVID-19 | ÀÓ»ó 1»ó (¹Ì±¹º¸°Ç¿¬±¸¿ø), Äڷγª Ä¡·áÁ¦ | ¡¡ | ¡¡ | & INFECTIOUS | NIT-118 | COVID-19 3 | ÀÓ»ó 1»ó (¿ö½ÌÅÏ´ë), Äڷγª Ä¡·áÁ¦ | ¡¡ | ¡¡ | DISEASES | NIT-105 | Vaccine Adjuvant: Elderly Cancer Survivors 3 | ÀÓ»ó 1»ó (¹Ì±¹º¸°Ç¿¬±¸¿ø) | ¡¡ | ¡¡ | ¡¡ | NIT-113 | Progressive Multifocal Leukoencephalopathy 3,5 | ÀÓ»ó 1»ó (¹Ì±¹º¸°Ç¿¬±¸¿ø) | ¡¡ | ¡¡ | ¡¡ | NIT-114 | Idiopathic CD4 Lymphocytopenia 3,6 | ÀÓ»ó 1»ó (¹Ì±¹º¸°Ç¿¬±¸¿ø) | ¡¡ | ¡¡ | OTHER | N/A | Acute Radiation Syndrome | ¡¡ | ¡¡ | ¡¡ | ¡¡ |
1. TNBC, NSCLC, SCLC, PaC, MSS-CRC | 2. Genexine sponsored; NIT co-funds under 3-way agreement with Merck | 3. Investigator-initiated trial | 4. Squamous Cell Carcinoma of Head and Neck, Window-of-Opportunity | 5. Orphan Drug Designation (US Jun 2020) | 6. Orphan Drug Designation (EU May 2017 US Apr 2019) |
|
¡Ø ÁÖÁÖÅä·Ð¹æÀÇ ±ÛÀº ³×ƼÁðÀÌ ÀÛ¼ºÇÑ ±Û·Î ´ç»ç¿Í ÀüÇô ¹«°üÇϸç ÃÖÁ¾Ã¥ÀÓÀº ÀÌ¿ëÀÚ¿¡°Ô ÀÖ½À´Ï´Ù. |
|
|
|
|
|
|
|
|
|
Àå¿ÜÁֽĽü¼, ºñ»óÀåÁֽĽü¼Ç¥ Á¤º¸Á¦°ø
ºñ»óÀåÁֽİŷ¡, Àå¿ÜÁֽĽÃÀå NO.1 38Ä¿¹Â´ÏÄÉÀ̼Ç
³×¿ÀÀ̹ÃÅØ ÁÖÁÖÅä·Ð¹æ,³×¿ÀÀ̹ÃÅØ ±â¾÷°³¿ä,³×¿ÀÀ̹ÃÅØ ÇöÀç°¡,³×¿ÀÀ̹ÃÅØ ÁÖ°¡,³×¿ÀÀ̹ÃÅØ °ü·Ã´º½º,³×¿ÀÀ̹ÃÅØ ÁÖ½Ä,³×¿ÀÀ̹ÃÅØ ±â¾÷°¡Ä¡,³×¿ÀÀ̹ÃÅØ ½ÇÀû,³×¿ÀÀ̹ÃÅØ ÁÖ´ç¼øÀÌÀÍ,³×¿ÀÀ̹ÃÅØ ¸ÅÃâ,³×¿ÀÀ̹ÃÅØ »óÀå,ÅõÀÚÀü·«,Á¾¸ñºÐ¼®,¼±¹°¿É¼Ç,ÇØ¿ÜÁõ½Ã,ÁֽĽü¼ µî Áõ±ÇÁ¤º¸,Áõ±ÇÁ¤º¸»çÀÌÆ®,Áõ±Ç½Ã¼¼,¼±¹°¿É¼Ç,ÁÖ°¡Á¤º¸,Á¾¸ñÅä·Ð,Àü¹®°¡,Å׸¶ÁÖ ºÐ¼®,ÃßõÁ¾¸ñ,À̽´,Á¾¸ñ´º½º,Â÷Æ®,½ÃȲÀü·«,ÁÖ½ÄÅõÀÚ,Áõ±Ç Àü¹® Æ÷ÅлçÀÌÆ®,ÀçÅ×Å©,ºÎµ¿»ê,â¾÷,Ä«Æä,ÁÖ½ÄÄ®·³,Áõ½Ãºê¸®ÇÎ,Áõ½ÃºÐ¼®,ÁÖ½ÄÅõÀÚÁ¤º¸,Áõ±ÇÅõÀÚÁ¤º¸,±ÝÀ¶Á¤º¸,Â÷Æ®ºÐ¼®,Áõ½ÃÀÏÁ¤,¼Ò¾×ÁÖÁÖ,Ä¿¹Â´ÏƼ,¸Å¸Å,Áֽİŷ¡,¿Â¶óÀÎÁõ±Ç,Á¾¸ñÃßÀü
ÁÖ½Ä,Æݵå,Áõ½ÃÀü¸Á,ÅõÀÚÆ÷ÅÐ »çÀÌÆ®,À繫ºÐ¼®,Áֽİø¸ð,Áõ½ÃÀÏÁ¤,Áõ±Ç»ç,ÄÚ½ºÇÇ,ÄÚ½º´Ú,³ª½º´Ú,°Å·¡¼Ò,ÁÖ°¡Áö¼ö,¹Ì±¹Áõ½Ã,ÀϺ»Áõ½Ã,¾Æ½Ã¾ÆÁõ½Ã,Äڳؽº,Á¦ÁÖ½Ä3½ÃÀå,KONEX,KOSCOM,ÆŽº³Ý,KOSDAQ,KOSPI,Àå¿ÜÁֽĻçÀÌÆ®,¼Ò¾×ÁÖÁÖ¸ðÀÓ,ºñ»óÀåÁֽİŷ¡»çÀÌÆ®
|